3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
13
Breast Neoplasms
12
Colorectal Neoplasms
11
Ovarian Neoplasms
10
Recurrence
9
Neoplasms
9
Small Cell Lung Carcinoma
8
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, Large B-Cell, Diffuse
7
Prostatic Neoplasms
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Carcinoma
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Recurrent Squamous Cell Lung Carcinoma
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Mesothelioma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Kidney Neoplasms
3
Interventions
Oxaliplatin
53
Cisplatin
52
Fluorouracil
50
Capecitabine
48
pembrolizumab
39
Leucovorin
31
Docetaxel
26
Trastuzumab
23
Paclitaxel
20
Irinotecan
20
Ramucirumab
13
Bevacizumab
12
Cetuximab
9
Radiotherapy
8
Surgical Procedures, Operative
7
S 1 (combination)
7
Nivolumab
7
Epirubicin
7
Carboplatin
6
olaparib
5
Platinum
5
Everolimus
5
Sunitinib
4
Mitomycin
4
trastuzumab deruxtecan
3
lenvatinib
3
epacadostat
3
bemarituzumab
3
apatinib
3
Saline Solution
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Stomach Neoplasms
×
durvalumab
×
Clear all
NCT02734004
2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2
Active not recruiting
264 enrolled
32 charts